Amylyx Pharmaceuticals (NASDAQ: AMLX) provided pre-launch commercial-readiness detail Tuesday September 1, 2026 as the company continues to advance toward NDA submission for avexitide (exendin-9-39, a GLP-1 receptor antagonist peptide) in post-bariatric hypoglycemia (PBH) following the August 18 Phase 3 LUCIDITY primary-endpoint hit (55% reduction in composite Level 2/3 hypoglycemic events, p=0.000003). Target NDA submission end of 2026; commercial launch preparation continues on schedule; and the company will use the upsized $500.2 million August 21 public offering to fund launch operations plus AMX0318 (long-acting follow-on peptide) IND-enabling studies. The Priority Review Voucher regime granted Arrowhead $215 million for plozasiran continues to shape the commercial economics of first-in-class peptide approvals in rare metabolic indications, and Amylyx is expected to be eligible if avexitide receives Breakthrough Therapy designation.
Amylyx Pharmaceuticals (NASDAQ: AMLX) upsized its underwritten public offering to $500.2 million from the initial $350 million announcement, pricing 14,090,000 shares of common stock at $35.50 per share Wednesday August 19, 2026. Expected closing: August 21, 2026, subject to customary closing conditions. Underwriter 30-day option: additional 2,113,500 shares at the same price less underwriting discounts and commissions, which would bring total raise capacity to roughly $575 million if fully exercised. Use of proceeds: avexitide (exendin 9-39, a peptide GLP-1 receptor antagonist) commercial launch preparation following the Monday August 18 LUCIDITY Phase 3 primary endpoint hit (55% reduction in composite Level 2/3 hypoglycemic events, p=0.000003, in post-bariatric hypoglycemia), NDA submission activities planned for end of 2026, AMX0318 (long-acting GLP-1 receptor antagonist candidate) IND-enabling studies with IND filing targeted 2027, and general corporate purposes. Dilution: as of June 30, 2026, Amylyx reported 111,368,283 shares outstanding; the 14.09 million new shares represent roughly 12.6% dilution on the base offering and 14.5% dilution including the underwriter overallotment. The upsize from $350M to $500.2M reflects the strong demand generated by the LUCIDITY win and the analyst reception (Guggenheim $55 PT, Mizuho $30, H.C. Wainwright $20, Seeking Alpha Strong Buy upgrade). Amylyx also expanded its board of directors as part of the capital markets round.